Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated

Journal of Clinical Oncology

Volumn 28, Issue 6, 2010, Pages 960-966

  Leyland Jones, Brian ^a   Colomer, Ramon ^a   Trudeau, Maureen E ^a   Wardley, Andrew ^a   Latreille, Jean ^a   Cameron, David ^a   Cubedo, Ricardo ^a   Al Sakaff, Nedal ^a   Feyereislova, Andrea ^a   Catalani, Olivier ^a   Fukushima, Yumi ^a   Brewster, Michael ^a   Cortés, Javier ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ADULT; AGED; ANAPHYLACTIC SHOCK; ARTHRALGIA; ARTICLE; BONE PAIN; BRAIN ISCHEMIA; BREAST CANCER; BREAST METASTASIS; BRONCHOSPASM; CARDIOTOXICITY; CHILL; CONSCIOUSNESS; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOXIA; INFECTION; LOADING DRUG DOSE; LOWER ABDOMINAL PAIN; LOWER RESPIRATORY TRACT INFECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL CHEST PAIN; NAUSEA; PAIN; PAIN IN EXTREMITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; TREATMENT RESPONSE; URINARY TRACT INFECTION; BLOOD; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 77949904451     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.1910     Document Type: Article

References (27)

1. HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
3. Wolff AC, Hammond MEH, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
4. National Comprehensive Cancer Network: NCCN practice guidelines in oncology, version 2.0: Breast cancer, 2007 update. http://www.nccn.org
5. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
6. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 (Pubitemid 29415219)
7. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
9. Bruno R, Washington CB, Lu JF, et al: Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369, 2005 (Pubitemid 41095399)
10. Roche: Herceptin Product Information: Annex I. Summary of product characteristics, 11/08 update. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Herceptin/H-278-PI-en.pdf
11. Leyland-Jones B: Dose scheduling: Herceptin. Oncology 61:31-36, 2001 (suppl 2)
12. Washington CB, Lieberman G, Liu P, et al: A population pharmacokinetic model for trastuzumab following weekly dosing. Clin Pharmacol Ther 71:2, 2002 (abstr MPI-30)
13. Leyland-Jones B, Baselga J, Latreille J, et al: A novel loading regimen for trastuzumab in metastatic breast cancer boosts serum levels in early cycles without compromising safety: Preliminary results. Presented at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference, Philadelphia, PA, November 14-18, 2005
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
15. Fukushima Y, Charoin J-E, Brewster M, et al: Population pharmacokinetic analysis of trastuzumab based on three different dosing regimens. Presented at the Annual Meeting of the Population Approach Group in Europe, Copenhagen, Denmark, June 13-15, 2007
16. Charoin J-E, Jacqmin P, Banken L, et al: Population pharmacokinetic analysis of trastuzumab following long-term administration using different regimens. Presented at the Annual Meeting of the Population Approach Group in Europe, Uppsala, Sweden, June 17-18, 2004
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
18. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
19. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: Second interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14-17, 2006 (abstr 52)
20. Smith I, Procter M, Gelber RD, et al: 2 year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
21. Leyland-Jones B, Gelmon K, Ayoub JP, et al: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971, 2003 (Pubitemid 46606210)
22. Baselga J, Carbonell X, Castañeda-Soto N-J, et al: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162-2171, 2005 (Pubitemid 46218708)
23. Marty M, Baselga J, Gatzemeier U, et al: Pooled analysis of six trials of trastuzumab (Herceptin): Exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate for clinical cardiac events. Breast Cancer Res Treat 82, 2003 (suppl 1; abstr 218)
24. Muehlbauer S, Revil C, Leyland-Jones B, et al: Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab (Herceptin). Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-14, 2008
25. Ewer SM, Ewer MS: Cardiotoxicity profile of trastuzumab. Drug Saf 31:459-467, 2008 (Pubitemid 351695459)
26. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
27. Nishimura R, Okumura Y, Arima N: Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: Time to progression and survival. Breast Cancer 15:57-64, 2008